← back to search

Robert Aiken

Overlook Medical Center · US
🔎 Find collaborators in Genetics · Immunology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Genetics · Immunology
Research interest
Research interests include Glioma Diagnosis and Treatment, Immunotherapy and Immune Responses, Cancer Research and Treatments, and CAR-T cell therapy research.
h-index
21
citations
2,748
works
97
NIH funding
primary concept
Medicine
email

Recent publications

Abstract LB081: Carboxyamidotriazole orotate (CTO) with temozolomide (TMZ) for recurrent high-grade gliomas (rHGG) and in combination with TMZ/RT->TMZ in newly diagnosed glioblastoma (ndGBM): Long term follow-up of phase IB trial
Cancer Research 2025cited by 0position: middledoi
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine 2023cited by 260position: middledoi
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
JAMA Oncology 2022cited by 391position: middledoi
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Journal of Experimental & Clinical Cancer Research 2022cited by 49position: middledoi
Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.
Journal of Clinical Oncology 2022cited by 27position: middledoi
LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)
Neuro-Oncology 2020cited by 26position: middledoi
LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology 2020cited by 8position: middledoi
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Clinical Cancer Research 2019cited by 270position: middledoi
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Journal of Translational Medicine 2018cited by 538position: middledoi
CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES
Neuro-Oncology 2018cited by 0position: middledoi
A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
Journal of Clinical Oncology 2014cited by 40position: middledoi
AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM
Neuro-Oncology 2014cited by 27position: middledoi
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme
Journal of Neuro-Oncology 2012cited by 35position: middledoi

Grants

Special Project: U.S. Attendance at the 16th World Computer Congress (IFIP Congress 2000)
NSF0001995$35,0002000–2002PIRePORTER
Problem Solving and Lifelong Learning: Developing and Assessing a Course in Information Technology
NSF9951418$384,9981999–2003PIRePORTER
Special Project: U.S. Attendance at the 14th IFIP World Computer Congress
NSF9628591$31,0001996–1998PIRePORTER
U.S. Attendance at the 13th IFIP World Computer Congress, Hamburg, Germany, August 28 - September 2, 1994
NSF9408078$26,0001994–1994PIRePORTER
FLAIR: Flexible Learning with an Artificial Intelligence Repository
NSF9115254$465,0001991–1996PIRePORTER
A Model Program for Retraining Elementary and Middle School Teachers to Use Computers Effectively in the Classroom
NSF8850521$366,9171988–1992PIRePORTER
Development of a Model Program for Preparing Computer Science Teachers at the Secondary School Level
NSF8550553$251,5451985–1988PIRePORTER
Travel to Attend: Conference on Microcomputers and Secondary Education; Paris France - April 15-18, 1980
NSF8006823$1,1441980–1980PIRePORTER

Frequent collaborators

Michael Glantz · Pennsylvania State University4 papers (2012–2019)David A. Reardon · Massachusetts Institute of Technology4 papers (2014–2022)Santosh Kesari · Santa Monica College4 papers (2014–2022)Surasak Phuphanich · Cedars-Sinai Medical Center3 papers (2014–2019) · 3 papers (2014–2019)Donald M. O’Rourke · Parker Institute for Cancer Immunotherapy3 papers (2014–2019)David M. Peereboom · Advocate Health Care3 papers (2014–2020)Michael L. Gruber · New York University3 papers (2014–2019)Karen Fink · University of Alabama at Birmingham3 papers (2014–2019)Renato V. LaRocca · University of Louisville3 papers (2014–2022)Glenn J. Lesser · Virginia Commonwealth University3 papers (2014–2019)Edward Pan · Southwestern Medical Center3 papers (2014–2019)William T. Curry · Political Research Associates3 papers (2014–2019)James M. Markert · University of Alabama at Birmingham3 papers (2014–2019) · 3 papers (2014–2019)Priya Kumthekar · Northwestern University2 papers (2020–2025)Patrick Y. Wen · Harvard University2 papers (2014–2019)Simon Khagi · Dartmouth–Hitchcock Medical Center2 papers (2020–2022)Thomas Kaley · Vanderbilt-Ingram Cancer Center2 papers (2020–2025)Howard Colman · University of Utah2 papers (2012–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Genetics · Immunology →